Tasly Pharmaceutical Hits Day Low of CNY 13.45 Amid Price Pressure

Tasly Pharmaceutical Group Co., Ltd. experienced a notable decline today, with the stock dropping by 4.45% on March 23, 2026. The stock reached an intraday low of CNY 13.45, reflecting ongoing challenges in its performance metrics. Over the past year, Tasly has faced a significant downturn, with a 10.52% decrease, contrasting sharply with the China Shanghai Composite, which has gained 13.33% during the same period. In terms of financial health, Tasly's net sales have contracted at an annual rate of 9.48% over the last five years, while operating profit has also seen a decline of 2.22%. Recent quarterly results indicate a net profit of CNY 112.86 million, down 55.59%, and the operating cash flow has reached its lowest point at CNY 912.93 million. The company's dividend payout ratio stands at 0%, further highlighting its current financial constraints. With a market capitalization of CNY 22,001 million, Tasly operates within the pharmaceuticals and biotechnology sector, but its long-term growth prospects appear limited, as evidenced by its performance relative to the broader market.